Loading data for INVA — first visit, this takes a few seconds.

Alerte

Innoviva Inc. (INVA)

NasdaqGS: INVA · Prix en temps réel · USD

21.25

+0.29 (1.38%)

À la clôture : Aug 18, 2026, 3:59 PM

21.43

+0.85%

Préouverture: 9:17 AM

1.38% (1D)

Cours acheteur	15.33
Capitalisation boursière	1.54B
Chiffre d’affaires (ttm)	440M
Résultat net (ttm)	357.24M
Bêta	0.34
EPS (ttm)	4.31
Ratio P/E (ttm)	4.93
P/E prévisionnel	9.62
P/B (ttm)	1.25
P/S (ttm)	3.49
Earnings Date	Nov 4, 2026

Cours vendeur	27.32
Volume	391,621
Volume moy. (20D)	838,812
Ouverture	21.24
Clôture précédente	20.96
Fourchette du jour	21.20 - 21.46
Intervalle de 52 semaines	16.52 - 25.15
Analyste	n/a
Objectif de prix	n/a
Dividendes	n/a
Date ex-dividende	8 sept. 2015

À propos de INVA

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pre...

[En savoir plus]

Industrie Biotechnology

Secteur Healthcare

Date d’introduction Oct 5, 2004

Employés 159

Bourse NasdaqGS

Symbole boursier INVA

Site web https://www.inva.com

Profil complet de l’entreprise

Performance financière

En 2025, le chiffre d’affaires de Innoviva s’élevait à 411.33M, soit une hausse de 14.67% par rapport aux 358.71M de l’année précédente. Le bénéfice s’élevait à 271.17M, soit une hausse de 1,059.22%.

États financiers

Surprise sur les résultats

Innoviva a publié ses résultats trimestriels le Aug 5, 2026 :

Chiffre d’affaires de $119.59M est inférieur aux estimations de $0, avec 19.25% croissance en glissement annuel.

EPS de 0.56 dépasse les estimations de 0.06, avec -27.27% Baisse en glissement annuel.

Prochaine publication des résultats

Innoviva Inc. devrait publier ses résultats le Nov 4, 2026, pendant les heures de marché.
Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure

Actualités

1 semaine il y a · Simply Wall St.

How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors

Innoviva, Inc. reported second-quarter 2026 results showing revenue of US$119.59 million, up from US$100.28 million a year earlier, but it moved from a net income of US$63.69 million to a net loss of ...

1 semaine il y a · Zacks

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva (INVA) delivered earnings and revenue surprises of +5.36% and +5.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 mois il y a · Insider Monkey

Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?

Innoviva, Inc. (NASDAQ:INVA) is one of the best cheap small cap stocks to buy now. Nortiva Bio, Inc., which is a wholly owned subsidiary of Innoviva, Inc. (NASDAQ:INVA), announced on June 18 its launc...

1 mois il y a · Insider Monkey

Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform

We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Innoviva, Inc. (NASDAQ:INVA) is one of the most promising stocks on our list. TheFly reported on ...

1 mois il y a · Insider Monkey

Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally

Innoviva Inc. (NASDAQ:INVA) is one of the most profitable undervalued stocks to invest in. On June 16, Innoviva Specialty Therapeutics entered an exclusive licensing and distribution agreement with Dr...

Page 1 de 2

Innoviva Inc. (INVA)